骨质疏松症治疗新选择——唑来膦酸

被引：24

作者：

陈瑾瑜

彭永德

盛正妍

机构：

[1] 上海交通大学附属第一人民医院内分泌代谢科

来源：

世界临床药物 | 2011年 / 32卷 / 04期

关键词：

骨质疏松; 骨量减少; 唑来膦酸; 不良反应;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

双膦酸盐是治疗骨质疏松症的一线药物。第3代双膦酸盐——唑来膦酸近年已进入国内临床应用,对治疗妇女绝经后骨质疏松症、糖皮质激素性骨质疏松症以及预防妇女绝经后骨量丢失等有效。然而,仍应高度重视本品可能引起的严重不良事件如下颌骨坏死、急性肾功能衰竭和心律失常等。

引用

页码：252 / 257

页数：6

共 9 条

[1]

Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older [J].

Boonen, Steven ;

Black, Dennis M. ;

Colon-Emeric, Cathleen S. ;

Eastell, Richard ;

Magaziner, Jay S. ;

Eriksen, Erik Fink ;

Mesenbrink, Peter ;

Haentjens, Patrick ;

Lyles, Kenneth W. .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 (02) :292-299

[2]

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial [J].

Reid, David M. ;

Devogelaer, Jean-Pierre ;

Saag, Kenneth ;

Roux, Christian ;

Lau, Chak-Sing ;

Reginster, Jean-Yves ;

Papanastasiou, Philemon ;

Ferreira, Alberto ;

Hartl, Florian ;

Fashola, Taiwo ;

Mesenbrink, Peter ;

Sambrook, Philip N. .

LANCET, 2009, 373 (9671) :1253-1263

[3]

Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study [J].

Sorensen, Henrik Toft ;

Christensen, Steffen ;

Mehnert, Frank ;

Pedersen, Lars ;

Chapurlat, Roland D. ;

Cummings, Steven R. ;

Baron, John A. .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7648) :813-816

[4]

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis [J].

Devogelaer, J. P. ;

Brown, J. P. ;

Burckhardt, P. ;

Meunier, P. J. ;

Goemaere, S. ;

Lippuner, K. ;

Body, J. J. ;

Samsioe, G. ;

Felsenberg, D. ;

Fashola, T. ;

Sanna, L. ;

Ortmann, C. E. ;

Trechsel, U. ;

Krasnow, J. ;

Eriksen, E. F. ;

Garnero, P. .

OSTEOPOROSIS INTERNATIONAL, 2007, 18 (09) :1211-1218

[5]

Compliance with drug therapies for the treatment and prevention of osteoporosis [J].

McCombs, JS ;

Thiebaud, P ;

McLaughlin-Miley, C ;

Shi, JH .

MATURITAS, 2004, 48 (03) :271-287

[6]

The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].

Caro, JJ ;

Ishak, KJ ;

Huybrechts, KF ;

Raggio, G ;

Naujoks, C .

OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008

[7]

Epidemiology and outcomes of osteoporotic fractures [J].

Cummings, SR ;

Melton, LJ .

LANCET, 2002, 359 (9319) :1761-1767

[8]

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [J].

Reginster, JY ;

Minne, HW ;

Sorensen, OH ;

Hooper, M ;

Roux, C ;

Brandi, ML ;

Lund, B ;

Ethgen, D ;

Pack, S ;

Roumagnac, I ;

Eastell, R .

OSTEOPOROSIS INTERNATIONAL, 2000, 11 (01) :83-91

[9]

Mortality after all major types of osteoporotic fracture in men and women: an observational study [J].

Center, JR ;

Nguyen, TV ;

Schneider, D ;

Sambrook, PN ;

Eisman, JA .

LANCET, 1999, 353 (9156) :878-882

← 1 →